Key facts
- This page summarizes Christopher Rovaldi's Form 4 filing for Keros Therapeutics, Inc. (KROS).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 19 Feb 2025, 16:15.
Christopher Rovaldi - 18 Feb 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)
- Signature
- /s/ Keith Regnante, Attorney-in-Fact
- Issuer symbol
- KROS
- Transactions as of
- 18 Feb 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 19 Feb 2025, 16:15:13 UTC
- Previous filing
- 15 Feb 2024
- SEC
- View on sec.gov
Key filing fact
Christopher Rovaldi filed Form 4 for Keros Therapeutics, Inc. (KROS) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 15 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
KROS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 18 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date. |